Ranbaxy, Nippon launch generic Clarith, Lamisil tablets in Japan

By Elaine Rigoli

Tampa, Fla., July 17 - Ranbaxy Laboratories Ltd. and Nippon Chemiphar Ltd. said Monday that as part of a joint venture, the companies have successfully launched clarithromycin 50 mg and 200 mg tablets and terbinafine 125 mg tablets in Japan.

Clarithromycin is sold by Taisho/Dinabbot under the brand name Clarith/Klaricid, and terbinafine is sold by Novartis under the brand name Lamisil.

Clarithromycin is an antibiotic and Terbinafine is an anti fungal; the market size is around $400 million and $300 million, respectively, in Japan, for the above dosage forms, the companies said.

The products will be sold in Japan under the Ranbaxy/Nihon label and will be marketed by both companies and promoted to doctors in hospitals as well as in clinics.

"It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio," Ranbaxy chief executive officer and managing director Malvinder Mohan Singh said in a news release.

Nippon Chemiphar is a research pharmaceutical company located in Tokyo.

Ranbaxy is a pharmaceutical research and development company based in Haryana, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.